Clinical Trial Update: Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating carboplatin and paclitaxel with or without the IGF-1R inhibitor CP-751,871 in advanced non-small cell lung cancer with squamous, aden…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenosquamous Carcinoma of the Lung
• Large Cell Carcinoma of the Lung
• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• CP-751,871 (dalotuzumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Squamous Cell, Carcinoma, Adenosquamous | Phase 3 | Status: TERMINATED | Results posted: 2013-12-03